Skip to main content

New Treatments in Testing to Slow or Stop Parkinson's

November 21, 2019

This is an archive file that took place on Thursday, November 21, 2019.

Our panelists discuss the latest trials of therapies that may slow or stop Parkinson's disease progression.

Webinar Details


Thursday, November 21, 2019


1 hr


12:00 pm ET
  • MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: November 21, 2019
    Date Credit Expires: November 21, 2021

    Learning Objectives

    At the conclusion of this course, participants should be able to:

    • Discuss the state of the Parkinson’s disease drug development pipeline.
    • Summarize therapies in clinical trial testing against alpha-synuclein, LRRK2 and GBA.
    • Describe repurposed therapies in Parkinson’s.
    • Explain therapies against other disease mechanisms and pathways, such as inflammation and oxidative stress.
    • Identify novel targets and innovative approaches under investigation for Parkinson’s.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Jamie Eberling, PhD -- Moderator
    Director, Research Programs
    The Michael J. Fox Foundation
    Nothing to Disclose

    Ken Marek, MD
    President and Senior Scientist, Institute for Neurodegenerative Disorders
    Principal Investigator, PPMI
    Disclosures: Advisory Role -- Consultant for MJFox Foundation, invicro, GE Healthcare, Prothena, Roche, Neuropore, Proclara, UCB, Takeda, Lysosomal Therapetic, Inc, Neuroderm, Denali, Neuron 23, Ceraspire, Samus, Samumed

    Todd Sherer, PhD
    CEO, The Michael J. Fox Foundation 
    Disclosure: Wife employed by Pfizer


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.